[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"her2neu-negative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:her2neu-negative":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100341312","s1703-serum-tumor-marker-directed-disease-monitoring-in-patients-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-100341312",false,"NCT03723928","S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer","Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer","Inclusion Criteria:\n\n* STEP 1 REGISTRATION\n* Patients must have a diagnosis of hormone receptor positive (estrogen receptor positive \\[ER+\\] and\u002For progesterone receptor positive \\[PR+\\]), HER-2 negative, metastatic (M1) breast cancer and must be receiving or plan to receive first-line systemic treatment for metastatic disease. (Systemic treatment is any treatment meant to treat the whole body such as endocrine therapy +\u002F- targeted therapy +\u002F- chemotherapy).\n\n  * NOTE: Participants are eligible if they have either de-novo metastatic breast cancer and\u002For recurrent breast cancer from an earlier stage that is now metastatic\n* Patients must be registered to step 1 between 14 days prior to and 60 days after start of first-line systemic treatment for metastatic disease\n* Patients must have been tested for the following breast cancer specific STMs after diagnosis of metastatic disease and within +\u002F-14 days of initiation of first-line systemic treatment for metastatic disease:\n\n  * CEA (must be tested)\n  * CA 15-3 or CA 27.29 (at least one of these must be tested)\n  * At least one of the tested STMs must have been \\>= 1.5 x the institutional upper limit of normal at this time.\n\nTesting all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring.\n\n* Patients must have systemic radiographic imaging prior to initiation of systemic therapy or within 30 days of initiation of treatment for metastatic breast cancer and prior to step 1 registration. Modality of imaging is at the discretion of the treating physician.\n\n  * Note: the treating physician can order additional imaging tests at any point prior to randomization at their discretion\n* Patients must be willing to obtain disease monitoring (imaging and\u002For serum tumor markers) from a consistent facility in which the registering site has access to the results for the duration of the study intervention (312 weeks after step 2 randomization). Imaging and STMs do not need to be completed at the same facility.\n* Patients with known cirrhosis, untreated B12 deficiency, thalassemia, or sickle cell anemia are not eligible as these could cause falsely elevated STM levels\n* Patients with known brain leptomeningeal metastases are not eligible as they may require regular radiographic monitoring to assess treatment response\n* Patients must not be currently enrolled or plan to participate in a first-line treatment trial for metastatic breast cancer with a defined monitoring schedule\n* Patients who are able to complete questionnaires in English or Spanish must participate in patient-reported outcome (PRO) assessments\n* Patients must not be pregnant due to the potential harm to the fetus from radiation exposure from radiographic imaging\n* Except for breast cancer (and previous history of breast cancer), no other prior malignancy is allowed with the following exceptions:\n\n  * Adequately treated basal (or squamous cell) skin cancer\n  * Any cancer from which the patient has been disease free for five years\n  * Prior Stage 0 or pre-cancerous lesions that have been removed with clear margins\n* Patients must not have received prior systemic therapy for metastatic breast cancer, except for their current line of therapy.\n* Patients must have decision making capacity and be able to provide informed consent\n* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; use of legally-authorized representative is not permissible for this study. Remote consent is allowed with adequate documentation.\n* As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\n* STEP 2 RANDOMIZATION\n* Patients must be tested for the breast cancer specific STMs that were tested prior to STEP 1 Registration between 56 and 140 days after initiation of first-line systemic therapy for metastatic disease:\n\n  * CEA (must be tested)\n  * CA 15-3 or CA 27.29 (whichever was tested prior to Step 1)\n\nTesting all three STMs is encouraged but only two are required. Patients must plan to have the same two STMs tested for the duration that the patient is on protocol-specified disease monitoring.\n\n* At least one of the STMs that was previously elevated must have decreased from the assessment at step 1 by \\>= 10% at this time.\n* Patients must not have known progression since registration to step 1\n* Patients must be registered to step 2 randomization between 56 days and 140 days after the initiation of first-line systemic therapy for metastatic disease; This window is inclusive; patients may be registered to Step 2 on day 56 or Day 140. Patients must have been eligible for Step 1 in order to be eligible for Step 2 Randomization\n* Baseline questionnaires must be completed within 28 days prior to step 2 randomization; (Note: Those patients who cannot complete the PRO questionnaires in English or Spanish can be registered to step 2 without contributing to PRO research)","ALL","18 Years",{"count":19,"type":20},739,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.",[26,27,28,29,30,31],"Anatomic Stage IV Breast Cancer AJCC v8","Estrogen Receptor Positive","HER2\u002FNeu Negative","Progesterone Receptor Positive","Prognostic Stage IV Breast Cancer AJCC v8","Elevated CA15-3 or CEA or CA27-29","RECRUITING","2026-04-01",{"date":35,"type":36},"2026-04-02","ACTUAL",{"date":38,"type":36},"2018-09-17",{"date":40,"type":20},"2036-12-01",{"name":42,"class":43},"SWOG Cancer Research Network","NETWORK",723,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100281599","multicenter-trial-for-eliminating-breast-cancer-surgery-or-radiotherapy-in-exceptional-responders-to-neoadjuvant-systemic-therapy-100281599","NCT02945579","Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","Inclusion Criteria:\n\n* Cohort A1 and A2\n\n  • Conditions for patient eligibility: Patients on this portion of the study can receive radiation treatment at any MD Anderson Cancer Center or any outside hospital and may be enrolled prior to, during, or following neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below:\n  1. Pathologically confirmed unicentric invasive breast cancer defined as radiologic clinical stage T1 or T2 (≤ 5 cm), N0 or N1 (≤ 4 abnormal axillary nodes on initial ultrasound), clinical stage M0.\n  2. HER2 positive (IHC 3+ and or FISH amplified) or triple receptor negative (TN, ER\u002FPR\\< 10% HER2 negative (IHC 1+ or 2+ FISH non-amplified) receiving any standard routine clinical NST regimen.\n  3. Patient desires breast conserving therapy.\n  4. Age 40 years or older. This age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences \\[124, 125\\].\n  5. Female sex.\n  6. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.\n  7. Patient must have an initial nodal ultrasound that does not demonstrate more than four suspicious lymph nodes, any suspicious lymph nodes should be biopsied to determine if nodal metastatic disease present.\n  8. Patient understands that the breast lesion size on final breast imaging must be less than or equal to 2 cm prior to the biopsy procedure being performed on study and if the biopsy shows residual carcinoma the patient will be taken off study.\n* Cohort B1 and B2\n\n  • Conditions for patient eligibility: Patients on this portion of the study will be limited to receive radiation treatment at MD Anderson Cancer Center or other approved locations and must be enrolled prior to any neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below:\n  1. ER and\u002For PR positive, HER2 negative\n  2. Clinical stage T1N0M0, unicentric non-lobular breast cancer, no lymphovascular space invasion,\n  3. At least 40 years of age.\n  4. Oncotype ≤ 25 if age ≥ 50 years\n  5. Oncotype 0-20 and tumor size ≤ 1.5cm if age 40-49 years.\n  6. Patient agrees to take anti-estrogen therapy and is interested in breast conservation\n  7. Female sex.\n  8. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.\n  9. No history of prior radiation to the area of the breast that would require protocol-mandated treatment\n* Cohort C\n\n  • Conditions for patient eligibility: Patients on this portion of the study can receive surgical treatment at any MD Anderson Cancer Center or any outside hospital and may be enrolled prior to or following neoadjuvant systemic therapy provided they meet the following eligibility and ineligibility requirements noted below:\n  1. Pathologically confirmed invasive breast cancer defined as radiologic clinical stage T1 or T2 (≤ 5 cm), N0, clinical stage M0 and HER2 positive (IHC 3+ and or FISH amplified) receiving any standard routine clinical NST regimen containing her-2 directed therapy OR Pathologically confirmed invasive breast cancer defined as radiologic clinical stage T1 (≤ 2 cm), N0, clinical stage M0 and triple negative, receiving any standard routine clinical NST regimen.\n  2. For cohort C patients participating in the optional pretreatment biopsy, the patient should be able undergo biopsy or surgery of the primary tumor site of suspected or proven invasive breast cancer and should be planned to receive neoadjuvant systemic therapy.\n  3. Patient desires breast conserving therapy.\n  4. Age 30 years or older if HER2 positive. Age 50 or older if HER2 negative (triple negative).\n  5. Female sex.\n  6. If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.\n  7. Patient must have an initial nodal ultrasound that does not demonstrate suspicious lymph nodes; any suspicious lymph nodes should be biopsied to determine if nodal metastatic disease present.\n  8. Patient must have no evidence of residual invasive tumor or DCIS on pathologic review of the lumpectomy surgical specimen\n  9. Patient must have no evidence of metastatic disease or isolated tumor cells involving the lymph nodes on pathologic review of the lymph node surgical specimen. If treatment effect in the nodes is noted on the pathology report, the investigators would generally discourage enrollment on this protocol.\n  10. Unifocal disease or limited multifocal disease that can be excised in a single lumpectomy specimen\n* Cohort D (MD Anderson Houston patients only)\n\n  * Conditions for patient eligibility: Patients on this portion of the study meet all eligibility requirements for cohort C, but have not enrolled onto the study to omit radiation. Patients in Cohort D can be identified at the time of diagnosis or prior to lumpectomy. They are not required to participate in one of the treatment arms of the study, but can ultimately choose to move to an omission Cohort at a later time point.\n\n3.5.1 Patients with triple negative or her-2 positive tumor who are amenable to breast conserving treatment and have received or are planned for neoadjuvant systemic therapy prior to surgery are eligible for Cohort D.\n\n3.5.2 Eligible patients in cohort D who have undergone optional ARTIDIS biopsies of the primary breast tumor at the time of diagnosis, prior to starting neoadjuvant therapy, or following completion of systemic therapy, at the time of surgery, may later move to Cohort A or C if they meet all eligibility requirements and ultimately desire surgery or radiation omission\n\nExclusion Criteria:\n\n1. Radiologic evidence for a stage T3 or clinical stage T4 breast cancer in Cohort A1\u002FA2\u002FC; radiologic evidence for a stage T2-T3 or clinical stage T4 breast cancer in Cohort B1\u002FB2.\n2. Clinical or pathologic evidence for distant metastases.\n3. Prior diagnosis of invasive or ductal carcinoma in situ breast cancer in the ipsilateral breast.\n4. Clinical evidence of progression of disease \\>20% in the breast or new evidence of nodal metastases.\n5. Patient is known to be pregnant.\n6. Patient is participating in a NST protocol in which surgical excision of the breast and or lymph nodes are required in Cohort A1\u002FA2\u002FB1\u002FB2.","FEMALE","30 Years",{"count":54,"type":20},120,[23],"This clinical trial studies eliminating surgery and\u002For radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radiotherapy with no surgery. In ER positive\u002FHER2 negative breast cancers, after endocrine therapy and ablative radiotherapy, when image-guided biopsy shows no residual cancer, patients then receive standard endocrine therapy with no surgery. For patients who have HER2 positive and triple negative breast cancers and standard surgery, after systemic therapy, breast radiotherapy is being eliminated when the pathology from surgery shows no residual cancer.",[58,59,28,60,61,62,63,64,65,66,67,68],"Estrogen Receptor Negative","HER2 Positive Breast Carcinoma","Invasive Breast Carcinoma","Progesterone Receptor Negative","Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Triple-Negative Breast Carcinoma","2026-03-05",{"date":71,"type":36},"2026-03-09",{"date":73,"type":36},"2017-01-20",{"date":75,"type":20},"2028-01-31",{"name":77,"class":78},"M.D. Anderson Cancer Center","OTHER",8,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100369455","phase-2-olaparib-with-cediranib-or-azd6738-for-the-treatment-of-advanced-or-metastatic-germline-brca-mutated-breast-cancer-100369455","NCT04090567","Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer","Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Women age greater than 18 years with advanced\u002Fmetastatic HER2 negative, BRCA germline positive breast cancer. Estrogen receptor positive (ER+) patients must have progressed on a prior endocrine therapy or are considered inappropriate for any FDA approved endocrine therapies for ER+ breast cancer.\n3. Eligible patients must agree to a mandatory fresh biopsy (excluding bone) at screening. In addition, if available, an archival tissue sample will also be collected at screening.\n4. Patients must have normal organ and bone marrow function measured within 28 days (baseline screening) as defined below:\n\n   * Hemoglobin (Hgb) \\>\u002F= 10.0 g\u002FdL with no blood transfusion in the past 28 days prior to the administration\n   * Absolute neutrophil count (ANC) \\>\u002F= 1.5 x 109\u002FL with no GCSF administration within 28 days prior to administration of study treatment\n   * Platelet count \\>\u002F= 100 x 109\u002FL\n   * Total bilirubin \\\u003C\u002F= 1.5 x institutional upper limit of normal (ULN)\n   * Aspartate aminotransferase (AST) \u002F Alanine aminotransferase (ALT) \\\u003C\u002F=3.0 x institutional upper limit of normal unless liver metastases are present in which case they must be \\\u003C\u002F=5x ULN\n\n4\\) Eastern Cooperative Oncology Group (ECOG) performance status 0-1 5) Patients must have life expectancy \\>\u002F= 16 weeks. 6) Negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Cycle 1 day 1 and during the study for child bearing potential women.\n\n• Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥ 60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry and be using highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female subjects if the risk of conception exists (Note: The effects of the trial treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in Appendix E or as stipulated in national or local guidelines). Highly effective contraception must be used 30 days prior to first trial treatment administration, for the duration of trial treatment, and at least for 1 month after stopping trial treatment.\n\n7\\) Patients is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations. 8) Patient has measurable disease, per RECIST v 1.1. At least one lesion, not previously irradiated or biopsied for this study that can be accurately measured at baseline as \\>\u002F= 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI).\n\n9\\) Willingness to undergo baseline biopsy of metastatic lesion (repeat biopsy at progression\u002For end of the study is optional) 10) Willingness to have research blood draw at baseline and at progression\u002Fend of the study 11) Patient should have previously treated with any PARP inhibitor ((neo)adjuvant or metastatic) setting) and must have remained on treatment for \\>\u002F= 2 months prior to progression of disease.\n\n12\\) Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of Olaparib or ceralasertib.\n\n13\\) Non-english speaking subject can be enrolled\n\nExclusion Criteria:\n\n1. Patients who have had chemotherapy or RT within 3 weeks ( or less than 1 week if on weekly chemotherapy) prior to start of the study agents. or persisting \\>\u002F= Grade 2 CTCAE toxicity (except alopecia and Grade 2 peripheral neuropathy) from previous anti-cancer treatment(s), or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier. No washout time period is needed for PARP inhibitors.\n2. Patients received any other investigational agents within the past 4 weeks.\n3. Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should be excluded from this clinical trial. Patient with known and treated brain metastases is allowed in this study if they fulfil the following criteria: The lesions have improved or remained stable radiographically and clinically for at least 6 weeks after completion of brain irradiation or stereotactic brain radiosurgery. Patients can be on steroids not more than 10 mg\u002Fday if started 4 weeks prior to initiation of study drug).\n4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Olaparib or ceralasertib.\n5. Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 (See Appendix A) are ineligible, unless discontinues within the washout period (2 weeks for CYP3A4 inhibitors and 4weeks for CYP3A4 inducers) as described in Appendix A. Dihydropyridine calcium-channel blockers are permitted for management of hypertension. Other medications described in Appendix A should be discontinued within the washout period prior to the initiation of study drugs. In addition, patients enrolled in Olaparib+ ceralasertib arm, co-administration of study drug with substrates of OATP1B1 and Pgp (P-glycoprotein) inhibitor or inducer is prohibited.\n6. Current use of natural herbal products (see Appendix A) or other complementary alternative medications (CAM) or \"folk remedies\" should be discontinued 7 days prior to the initiation of study drugs.\n\n8\\) Patients with concomitant or prior invasive malignancies within the past 5 years. Subjects with treated limited stage basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are eligible.\n\n9\\) Uncontrolled inter-current illness including, but not limited to, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan, ongoing or active infection, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n\n10\\) History of myocardial infarction, stroke or transient ischemic attack within 6-12 months. Current condition requiring concurrent use of drugs or biologics with anti-arrhythmic or proarrhythmic potential 11) History of hypertensive crisis or hypertensive encephalopathy within 3 years.\n\n12\\) Clinically significant peripheral vascular disease or vascular disease (abdominal aortic aneurysm (\\>5cm) or aortic dissection). If known history of abdominal aortic aneurysmwith\n\n* 4cm in diameter, all the following criteria must be met:\n\n  * An ultrasound (US) within the last 6 months will be required to document that it is \\\u003C\u002F= 5cm\n  * Patient must be asymptomatic from the aneurysm.\n\n    13\\) A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting study drug (percutaneous\u002Fendobronchial biopsies are allowed). The patient must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment.\n\n    14\\) Patients may not have current signs and\u002For symptoms of bowel obstruction within 3 months prior to starting study drugs, except if it was a temporary incident (improved within \\\u003C 24hrs with medical management).\n\n    15)History of haemoptysis or any significant bleeding within the last 1 month prior to enrolment. 16) Presence of cavitation of central pulmonary lesion 17) Intra-abdominal abscess within the 3 months prior to enrolment. Patient with history of GI perforation. History of abdominal fistula will be considered eligible, if the fistula was surgically repaired, there has been no evidence of fistula for at least 6 months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula.\n\n    18\\) Patients may have current dependency on IV hydration or total parenteral nutrition (TPN).\n\n    19\\) Patients may have features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated. 20) As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, active bleeding diatheses, renal transplant, or active infection including any patient known to have hepatitis B, hepatitis C and human immunodeficiency virus (HIV).\n\nScreening for chronic conditions is not required 21) Any condition that, in the opinion of the treating investigator would interfere with evaluation of the investigational product or interpretation of subject safety or study results.\n\n22\\) Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n\n23\\) Prior exposure to Ceralasertib 24) Patients with uncontrolled seizure 25) Any of the following cardiac criteria:\n\n* Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \\>450 milli-second, or patients with congenital long QT syndrome or family history of unexplained sudden death under 40 years of age\n* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block).\n\n  26\\) Patients at risk of brain perfusion problems, e.g., carotid stenosis 27) Patients with relative hypotension (\\\u003C 100\u002F60 mm Hg) or clinically relevant orthostatic hypotension (\\>\u002F= 20 beats per minute change in pulse including a fall in blood pressure of\n\n  \\>\u002F=20mm Hg associated with dizziness, syncope, and blurred vision, from lying down or sitting to standing). Uncontrolled hypertension requiring clinical intervention.\n\n  28\\) Breast feeding\u002Flactating\u002Fpregnant women. 29) Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation.\n\n  30\\) A diagnosis of ataxia telangiectasia 31) Major surgery within 3 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.",{"count":88,"type":20},60,[90],"PHASE2","This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",[93,94,95,96,97,26,98,99,28,100,101,102,103,104,30],"Advanced Breast Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Germline BRCA1 Gene Mutation","Germline BRCA2 Gene Mutation","Metastatic Breast Carcinoma","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","2026-03-03",{"date":69,"type":36},{"date":108,"type":36},"2020-07-28",{"date":110,"type":20},"2027-12-31",{"name":77,"class":78},1]